Remegen's Novel Medication Telitacicept (RC18) Achieves Favorable Phase III Outcomes, Applied for a Secondary Use in Managing Rheumatoid Arthritis.

Me-too drugs specifically refer to drugs with their own intellectual property rights, whose efficacy is comparable to that of innovative breakthrough drugs.

This article summarized the latest R&D progress of Deutetrabenazine, the Mechanism of Action for Deutetrabenazine, and the drug target R&D trends for Deutetrabenazine.

Mesentech recently revealed that its Phase 1 trial has begun, and the initial patients have already received their doses of MES1022.

This article summarized the latest R&D progress of Deoxycholic acid, the Mechanism of Action for Deoxycholic acid, and the drug target R&D trends for Deoxycholic acid.

Elpiscience Biopharmaceuticals has revealed that the initial patient has received a dose in a Phase 1 clinical study of the anti-LILRB2 monoclonal antibody ES009 in Australia.

Me-better class of innovative drugs refers to new drugs that have clinical efficacy or safety superior to that of the original innovative drug.

This article summarized the latest R&D progress of Decitabine, the Mechanism of Action for Decitabine, and the drug target R&D trends for Decitabine.

FIC stands for First in Class, which refers to pioneering drugs.

Edgewise Therapeutics, Inc., has initiated the participation induction for GRAND CANYON, an international principal examination of EDG-5506 designed for Becker patients.

This article summarized the latest R&D progress of Crisaborole, the Mechanism of Action for Crisaborole, and the drug target R&D trends for Crisaborole.

Arcturus Therapeutics and the Cystic Fibrosis Foundation continue partnership to further the development of ARCT-032, an experimental mRNA therapy for Cystic Fibrosis.